Short answer
Embecta Corp. (EMBC) filed its Q4 2025 10-Q quarterly report on Feb 5, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $261M (down 0.3% year over year) with net income of $44M.
Q4 2025 key financials · XBRL
- Revenue
- $261M
- −0.3% YoY
- Net income
- $44M
- Operating margin
- 31.9%
- Gross margin
- 61.9%
- EPS (diluted)
- $0.74
Source: XBRL data from the Embecta Corp. (EMBC) Q4 2025 10-Q on SEC EDGAR. USD.
Embecta Corp. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $261.2M, down $0.7M or 0.3% YoY from $261.9M
- Gross margin 61.9% vs 60.0% YoY; operating income $83.3M vs $28.7M
- Revenue headwind from $7.8M unfavorable pricing; favorable volume $3.2M
- Cash $204.4M vs $228.6M; operating cash flow $17.2M and debt payments $37.5M
- Tariffs, supply-chain inflation, pricing pressure, and diabetes drug adoption as near-term headwinds
Risk Factors
- No material changes to risk factors from Embecta’s 2025 Form 10-K
- Carried-forward risks remain the principal regulatory, operational, competitive, and financial exposures disclosed in the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Embecta Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.